Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab

CONCLUSIONS: R/R LBCL patients reported consistent, clinically meaningful improvements in symptoms and HRQoL and satisfaction with epcoritamab.PMID:38151388 | DOI:10.1016/j.clml.2023.11.005

Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Tycel Phillips Pieternella Lugtenburg Anupama Kalsekar Alex Mutebi Anthony Wang Julie Blaedel Katherine Kosa Susan Martin Mariana Sacchi Nurgul Kilavuz Catherine Thieblemont Source Type: research